SEC Form 4 · accession 0001387131-18-001127
TherapeuticsMD, Inc. · TXMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchell Krassan
Officer — Chief Strategy Officer
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000025743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $5.16 | Mar 15, 2018 | A | 170,000 | A | Mar 15, 2019 | Mar 15, 2028 | Common Stock | 170,000 | 170,000 | D |
Explanation of responses
- F1Underlying shares vest as follows: 56,667 shares on the first anniversary date of the grant, 56,667 shares on the second anniversary date of the grant, and 56,666 shares on the third anniversary date of the grant.